In the US, Zaroxolyn (metolazone systemic) is a member of the drug class thiazide diuretics and is used to treat Edema and High Blood Pressure.
US matches:
Metolazone is reported as an ingredient of Zaroxolyn in the following countries:
International Drug Name Search
Antithrombin III Immuno may be available in the countries listed below.
Antithrombin III is reported as an ingredient of Antithrombin III Immuno in the following countries:
International Drug Name Search
Betlol SR may be available in the countries listed below.
Bezafibrate is reported as an ingredient of Betlol SR in the following countries:
International Drug Name Search
Fatroxid may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Benzoyl Peroxide is reported as an ingredient of Fatroxid in the following countries:
International Drug Name Search
Felodipine-EG may be available in the countries listed below.
Felodipine is reported as an ingredient of Felodipine-EG in the following countries:
International Drug Name Search
Relafin may be available in the countries listed below.
Fluvoxamine maleate (a derivative of Fluvoxamine) is reported as an ingredient of Relafin in the following countries:
International Drug Name Search
In the US, Cepastat is a member of the drug class mouth and throat products and is used to treat Tonsillitis/Pharyngitis.
Phenol is reported as an ingredient of Cepastat in the following countries:
International Drug Name Search
Clarithromycin Alternova may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Clarithromycin Alternova in the following countries:
International Drug Name Search
Bicalutamid Hikma may be available in the countries listed below.
Bicalutamide is reported as an ingredient of Bicalutamid Hikma in the following countries:
International Drug Name Search
Colchicina Phoenix may be available in the countries listed below.
Colchicine is reported as an ingredient of Colchicina Phoenix in the following countries:
International Drug Name Search
Amminosidina may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Paromomycin sulfate (a derivative of Paromomycin) is reported as an ingredient of Amminosidina in the following countries:
International Drug Name Search
Eviol-A may be available in the countries listed below.
Retinol acetate (a derivative of Retinol) is reported as an ingredient of Eviol-A in the following countries:
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Eviol-A in the following countries:
International Drug Name Search
Furosemid Nycomed may be available in the countries listed below.
Furosemide is reported as an ingredient of Furosemid Nycomed in the following countries:
International Drug Name Search
Atropinol may be available in the countries listed below.
Atropine is reported as an ingredient of Atropinol in the following countries:
International Drug Name Search
Nitrostad Retard may be available in the countries listed below.
Nitroglycerin is reported as an ingredient of Nitrostad Retard in the following countries:
International Drug Name Search
Tromboliz may be available in the countries listed below.
Dipyridamole is reported as an ingredient of Tromboliz in the following countries:
International Drug Name Search
Superocin may be available in the countries listed below.
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Superocin in the following countries:
International Drug Name Search
Dospir may be available in the countries listed below.
Ipratropium Bromide is reported as an ingredient of Dospir in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Dospir in the following countries:
International Drug Name Search
Itrakonazol Sandoz may be available in the countries listed below.
Itraconazole is reported as an ingredient of Itrakonazol Sandoz in the following countries:
International Drug Name Search
Normolip may be available in the countries listed below.
Fenofibrate is reported as an ingredient of Normolip in the following countries:
Gemfibrozil is reported as an ingredient of Normolip in the following countries:
International Drug Name Search
Wymesone may be available in the countries listed below.
Dexamethasone is reported as an ingredient of Wymesone in the following countries:
International Drug Name Search
Avlezan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Flunixin meglumine (a derivative of Flunixin) is reported as an ingredient of Avlezan in the following countries:
International Drug Name Search
Lidocain-Rotexmedica may be available in the countries listed below.
Lidocaine hydrochloride monohydrate (a derivative of Lidocaine) is reported as an ingredient of Lidocain-Rotexmedica in the following countries:
International Drug Name Search
Antirrinum may be available in the countries listed below.
Oxymetazoline hydrochloride (a derivative of Oxymetazoline) is reported as an ingredient of Antirrinum in the following countries:
International Drug Name Search
QuinaLich comp may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of QuinaLich comp in the following countries:
Quinapril hydrochloride (a derivative of Quinapril) is reported as an ingredient of QuinaLich comp in the following countries:
International Drug Name Search
Aknefug Doxy may be available in the countries listed below.
Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Aknefug Doxy in the following countries:
International Drug Name Search
Ultracain Epinefrina may be available in the countries listed below.
Articaine is reported as an ingredient of Ultracain Epinefrina in the following countries:
Epinephrine hydrochloride (a derivative of Epinephrine) is reported as an ingredient of Ultracain Epinefrina in the following countries:
International Drug Name Search
Betacap may be available in the countries listed below.
UK matches:
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Betacap in the following countries:
International Drug Name Search
Glossary
| SPC | Summary of Product Characteristics (UK) |
In the US, SSKI (potassium iodide systemic) is a member of the following drug classes: antithyroid agents, expectorants and is used to treat Cough, Cutaneous Sporotrichosis, Hyperthyroidism and Radiation Emergency.
US matches:
Potassium Iodide is reported as an ingredient of SSKI in the following countries:
International Drug Name Search
Synpezil may be available in the countries listed below.
Donepezil hydrochloride (a derivative of Donepezil) is reported as an ingredient of Synpezil in the following countries:
International Drug Name Search
Aldesleuchina may be available in the countries listed below.
Aldesleuchina (DCIT) is known as Aldesleukin in the US.
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
Ladybon may be available in the countries listed below.
Tibolone is reported as an ingredient of Ladybon in the following countries:
International Drug Name Search
Antoxine may be available in the countries listed below.
Dihydroergotamine is reported as an ingredient of Antoxine in the following countries:
International Drug Name Search
Piroxicam Dorom may be available in the countries listed below.
Piroxicam is reported as an ingredient of Piroxicam Dorom in the following countries:
International Drug Name Search
Voltfast may be available in the countries listed below.
Diclofenac potassium salt (a derivative of Diclofenac) is reported as an ingredient of Voltfast in the following countries:
International Drug Name Search
Acido Alendronico Semanal Farmalider may be available in the countries listed below.
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Acido Alendronico Semanal Farmalider in the following countries:
International Drug Name Search
Anxer may be available in the countries listed below.
Cefalexin is reported as an ingredient of Anxer in the following countries:
International Drug Name Search
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules and other antibacterial drugs, Dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Dicloxacillin sodium, USP is an antibacterial agent of the isoxazolyl penicillin series. It is a penicillinase-resistant, acid resistant semisynthetic penicillin suitable for oral administration.
Dicloxacillin sodium is chemically designated as 4-Thia-1-azabicyclo [3.2.0]heptane-2-carboxylic acid, 6-[[[3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]-carbonyl]-amino]-3,3-dimethyl-7-oxo-, monosodium salt, monohydrate, [2S-(2α5α,6β)] and has the following structural formula:
Each capsule for oral administration contains Dicloxacillin sodium equivalent to 250 or 500 mg of Dicloxacillin. The inactive ingredients are gelatin, FD&C Blue #1, magnesium stearate, and titanium dioxide.
Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.
Dicloxacillin sodium has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
Staphylococcus spp. (penicillinase producing)
Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure1,2 that has been recommended for use with disks to test the susceptibility of microorganisms to Dicloxacillin, uses the 1 mcg oxacillin disk. Interpretation involves correlation of the diameter obtained in the disk test with the minimum inhibitory concentration (MIC) for Dicloxacillin.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 1 mcg oxacillin disk should be interpreted according to the criteria provided in Table 1.
Quantitative methods that are used to determine minimum inhibitory concentrations (MICs) provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure1,3 uses a standardized dilution method (broth or agar) or equivalent with oxacillin powder. The MIC values obtained should be interpreted according to the criteria provided in Table 1.
| Susceptibility Test Result Interpretive Criteria | ||||||
| Pathogen | Disk diffusion (Zone diameter in mm) | Minimal Inhibitory Concentration (MIC in mcg/mL) | ||||
| S | I | R | S | I | R | |
| S.aureus | ≥ 13 | 11-12 | ≤ 10 | ≤ 2 | - | ≥ 4 |
| Coagulase-negative staphylococci | ≥ 18 | - | ≤ 17 | ≤ 0.25 | - | ≥ 0.5 |
A report of Susceptible (S) indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in the blood. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.
Measurement of MIC and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some infections. (See CLINICAL PHARMACOLOGY section for further information on drug concentrations achieved in infected body sites and other pharmacokinetic properties of this antimicrobial drug product.)
Standardized susceptibility test procedures require the use of laboratory control microorganisms.1,2,3 The 1 mcg oxacillin disk and the standard oxacillin powder should provide respectively the following zone diameters and MIC values in these laboratory test quality control strains:
| Acceptable Quality Control Ranges | ||
| Microorganism | Disk Diffusion (Zone diameter ranges in mm) | Minimal Inhibitory Concentration Range (MIC in mcg/mL) |
| Enterococcus faecalis ATCC® 29212 | - | 8 - 32 |
| Staphylococcus aureus ATCC® 25923 | 18 - 24 | - |
| Staphylococcus aureus ATCC® 29213 | - | 0.12 - 0.5 |
| Streptococcus pneumoniae ATCC® 49619 | ≤ 12 | - |
Dicloxacillin sodium, USP is resistant to destruction by acid. Absorption of Dicloxacillin sodium after oral administration is rapid but incomplete. Food in the gastrointestinal tract decreases the absorption of Dicloxacillin. Studies with an oral dose of 125 mg gave average serum levels at 60 minutes of 4.74 mcg/mL. At four hours, average levels were 0.62 mcg/mL. In one study, single oral doses of Dicloxacillin sodium 500 mg produced peak serum concentrations of 10 to 17 mcg/mL at 1 to 1.5 hours.
Once absorbed, Dicloxacillin sodium is 95% to 99% bound to serum proteins, mainly albumin.
Dicloxacillin sodium, with normal doses, has insignificant concentrations in the cerebrospinal and ascitic fluids. It is found in therapeutic concentrations in the pleural, bile, and amniotic fluids. Dicloxacillin sodium is rapidly excreted as unchanged drug in the urine by glomerular filtration and active tubular secretion. The elimination half-life for Dicloxacillin sodium is about 0.7 hours.
Dicloxacillin is not dialyzable. Only minimal amounts are removed by hemodialysis or peritoneal dialysis.
The penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. Cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing).
The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Dicloxacillin sodium capsules and other antibacterial drugs, Dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.
Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have occurred in patients receiving penicillin. The incidence of anaphylactic shock in all penicillin-treated patients is between 0.015 and 0.04 percent. Anaphylactic shock resulting in death has occurred in approximately 0.002 percent of the patients treated. Although anaphylaxis is more frequent following a parenteral administration, it has occurred in patients receiving oral penicillins.
When penicillin therapy is indicated, it should be initiated only after a comprehensive patient drug and allergy history has been obtained. If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, eg, artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. Individuals with a history of penicillin hypersensitivity may also experience allergic reactions when treated with a cephalosporin.
Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Dicloxacillin sodium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Penicillinase-resistant penicillins should generally not be administered to patients with a history of sensitivity to any penicillin.
Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. There is clinical and laboratory evidence of partial cross-allergenicity among penicillins and other β-lactam antibiotics including cephalosporins, cephamycins, and other 1-oxa-β-lactams. Whenever allergic reactions occur, penicillin should be withdrawn unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to penicillin therapy.
The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilation, cardiospasm, or intestinal hypermotility. Occasionally patients will not absorb therapeutic amounts of orally administered penicillin.
Prescribing Dicloxacillin sodium capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Patients receiving penicillins should be given the following information and instructions by the physician:
Patients should be counseled that antibacterial drugs including Dicloxacillin sodium capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Dicloxacillin sodium capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Dicloxacillin sodium capsules or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Bacteriologic studies to determine the causative organisms and their susceptibility to the penicillinase-resistant penicillins should be performed (see CLINICAL PHARMACOLOGY-Microbiology). In the treatment of suspected staphylococcal infections, therapy should be changed to another active agent if culture tests fail to demonstrate the presence of staphylococci.
Periodic assessment of organ system function including renal, hepatic, and hematopoietic should be made during prolonged therapy with the penicillinase-resistant penicillins.
Blood cultures, white blood cell, and differential cell counts should be obtained prior to initiation of therapy and at least weekly during therapy with penicillinase-resistant penicillins.
Periodic urinalysis, blood urea nitrogen, and creatinine determinations should be performed during therapy with the penicillinase-resistant penicillins and dosage alterations should be considered if these values become elevated. If any impairment of renal function is suspected or known to exist, a reduction in the total dosage should be considered and blood levels monitored to avoid possible neurotoxic reactions (see DOSAGE AND ADMINISTRATION).
AST (SGOT) and ALT (SGPT) values should be obtained periodically during therapy to monitor for possible liver function abnormalities.
Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
Probenecid administered concomitantly with penicillins increases and prolongs serum penicillin levels (see DOSAGE AND ADMINISTRATION).
Penicillinase-resistant penicillins, like other penicillins, are physically and/or chemically incompatible with aminoglycosides and can inactivate the drugs in vitro. In vitro mixing of penicillins and aminoglycosides should be avoided during concomitant therapy and the drugs should be administered separately. Penicillins can inactivate aminoglycosides in vitro in serum samples from patients receiving both drugs, which could produce falsely decreased results in serum aminoglycoside assays of the serum samples.
Dicloxacillin may reduce the anticoagulant response to dicumarol and warfarin. Careful monitoring of prothrombin times is suggested during concomitant therapy, and dosage of the anticoagulant should be adjusted as required. The mechanism of this possible interaction is unclear, but may be due to hepatic enzyme induction.
No long-term animal studies have been conducted with these drugs.
Studies on reproduction (nafcillin) in rats and rabbits reveal no fetal or maternal abnormalities before conception and continuously through weaning (one generation).
Reproduction studies performed in the mouse, rat, and rabbit have revealed no evidence of impaired fertility or harm to the fetus due to the penicillinase-resistant penicillins. Human experience with the penicillins during pregnancy has not shown any positive evidence of adverse effects on the fetus. There are, however, no adequate or well-controlled studies in pregnant women showing conclusively that harmful effects of these drugs on the fetus can be excluded. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Penicillins are excreted in breast milk. Caution should be exercised when penicillins are administered to a nursing woman.
Because of incompletely developed renal function in newborns, penicillinase-resistant penicillins (especially methicillin) may not be completely excreted, with abnormally high blood levels resulting. Frequent blood levels are advisable in this group with dosage adjustments when necessary. All newborns treated with penicillin should be monitored closely for clinical and laboratory evidence of toxic or adverse effects (see DOSAGE AND ADMINISTRATION). Experience in the neonatal period is limited. Therefore a dose for the newborn is not recommended.
Clinical studies of Dicloxacillin sodium capsules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Rare reports have been received during postmarketing surveillance of esophageal burning, esophagitis, and esophageal ulceration, particularly after ingestion of Dicloxacillin capsules with an insufficient quantity of water and/or before going to bed. To minimize the risk of developing such events, Dicloxacillin should be taken with at least 4 fluid ounces (120 mL) of water and Dicloxacillin should NOT be taken in the supine position or immediately before going to bed.
The reported incidence of allergic reactions to penicillin ranges from 0.7 to 10 percent (see WARNINGS). Sensitization is usually the result of treatment but some individuals have had immediate reactions to penicillin when first treated. In such cases, it is thought that the patients may have had prior exposure to the drug via trace amounts present in milk and vaccines.
Two types of allergic reactions to penicillin are noted clinically, immediate and delayed.
Immediate reactions usually occur within 20 minutes of administration and range in severity from urticaria and pruritus to angioneurotic edema, laryngospasm, bronchospasm, hypotension, vascular collapse, and death. Such immediate anaphylactic reactions are very rare (see WARNINGS) and usually occur after parenteral therapy but have occurred in patients receiving oral therapy. Another type of immediate reaction, an accelerated reaction, may occur between 20 minutes and 48 hours after administration and may include urticaria, pruritus, and fever. Although laryngeal edema, laryngospasm, and hypotension occasionally occur, fatality is uncommon.
Delayed allergic reactions to penicillin therapy usually occur after 48 hours and sometimes as late as 2 to 4 weeks after initiation of therapy. Manifestations of this type of reaction include serum sickness-like symptoms (ie, fever, malaise, urticaria, myalgia, arthralgia, abdominal pain) and various skin rashes.
Nausea, vomiting, diarrhea, stomatitis, black or hairy tongue, and other symptoms of gastrointestinal irritation may occur, especially during oral penicillin therapy.
Pseudomembranous colitis has been reported with the use of Dicloxacillin. Therefore, it is important to consider its diagnosis in patients who develop diarrhea in association with Dicloxacillin use.
Rare reports have been received during postmarketing surveillance of esophageal burning, esophagitis, and esophageal ulceration, particularly after ingestion of Dicloxacillin capsules with an insufficient quantity of water and/or before going to bed (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Neurotoxic reactions similar to those observed with penicillin G (e.g., lethargy, confusion, twitching, multifocal myoclonus, localized or generalized epileptiform seizures) may occur with large intravenous doses of the penicillinase-resistant penicillins especially in patients with renal insufficiency.
Renal tubular damage and interstitial nephritis have been associated with the administration of methicillin sodium and infrequently with the administration of nafcillin and oxacillin. Manifestations of this reaction may include rash, fever, eosinophilia, hematuria, proteinuria, and renal insufficiency. Methicillin-induced nephropathy does not appear to be dose-related and is generally reversible upon prompt discontinuation of therapy.
Eosinophilia, hemolytic anemia, agranulocytosis, neutropenia, leukopenia, granulocytopenia, thrombocytopenia, and bone marrow depression have been associated with the use of penicillinase-resistant penicillins.
Hepatotoxicity, characterized by fever, nausea, and vomiting associated with abnormal liver function tests, mainly elevated SGOT levels, has been associated with the use of oxacillin and cloxacillin. Cholestatic hepatitis has been reported rarely. Asymptomatic, transient increases in serum concentrations of alkaline phosphatase, AST (SGOT), and ALT (SGPT) have been reported.
The penicillinase-resistant penicillins are available for oral administration and for intramuscular and intravenous injection. The sodium salts of methicillin, oxacillin, and nafcillin may be administered parenterally and the sodium salts of cloxacillin, Dicloxacillin, oxacillin, and nafcillin are available for oral use.
Bacteriologic studies to determine the causative organisms and their sensitivity to the penicillinase-resistant penicillins should always be performed. Duration of therapy varies with the type and severity of infection as well as the overall condition of the patient, therefore, it should be determined by the clinical and bacteriological response of the patient. In severe staphylococcal infections, therapy with penicillinase-resistant penicillins should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. The treatment of endocarditis and osteomyelitis may require a longer term of therapy.
Concurrent administration of the penicillinase-resistant penicillins and probenecid increases and prolongs serum penicillin levels. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Penicillin-probenecid therapy is generally limited to those infections where very high serum levels of penicillin are necessary.
Oral preparations of the penicillinase-resistant penicillins should not be used as initial therapy in serious, life-threatening infections (see PRECAUTIONS–General). Oral therapy with the penicillinase-resistant penicillins may be used to follow-up the previous use of a parenteral agent as soon as the clinical condition warrants. For intramuscular gluteal injections, care should be taken to avoid sciatic nerve injury. With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.
| DRUG | ADULTS | CHILDREN | ||
| Mild to Moderate | Severe | Mild to Moderate | Severe | |
| ||||
| Dicloxacillin | 125 mg every 6 hours | 250 mg every 6 hours | 12.5 mg/kg/ day* in equally divided doses every 6 hours | 25 mg/kg/ day* in equally divided doses every 6 hours |
Dicloxacillin is best absorbed when taken on an empty stomach, and should be administered at least 1 hour before or 2 hours after meals. Dicloxacillin should be taken with at least 4 fluid ounces (120 mL) of water and should not be be taken in the supine position or immediately before going to bed (see PRECAUTIONS).
Dicloxacillin sodium capsules, USP
| 250 mg | Light blue cap/body capsule printed with GG854 containing Dicloxacillin sodium equivalent to 250 mg Dicloxacillin. Bottle of 100 capsules NDC 0781-2248-01 |
| 500 mg | Light blue cap/body capsule printed with GG855 containing Dicloxacillin sodium equivalent to 500 mg Dicloxacillin. Bottle of 100 capsules NDC 0781-2258-01 |
Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].
08-2009
46018688
Manufactured in Austria by Sandoz GmbH
Distributed by Sandoz Inc., Princeton, NJ 08540
NDC 0781-2248-01
Dicloxacillin
Sodium
Capsules, USP
250 mg
Rx only
100 Capsules
SANDOZ
NDC 0781-2258-01
Dicloxacillin
Sodium
Capsules, USP
500 mg
Rx only
100 Capsules
SANDOZ
| Dicloxacillin SODIUM Dicloxacillin sodium capsule | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA061454 | 04/01/1971 | |
| Dicloxacillin SODIUM Dicloxacillin sodium capsule | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA061454 | 04/01/1971 | |
| Labeler - Sandoz Inc (110342024) |
Doxazosine CF may be available in the countries listed below.
Doxazosin mesilate (a derivative of Doxazosin) is reported as an ingredient of Doxazosine CF in the following countries:
International Drug Name Search
Carbaglu is a brand name of carglumic acid, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Carbaglu available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carbaglu. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Carbaglu.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Amlozek may be available in the countries listed below.
Amlodipine is reported as an ingredient of Amlozek in the following countries:
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlozek in the following countries:
International Drug Name Search
AC Vascular may be available in the countries listed below.
Nimodipine is reported as an ingredient of AC Vascular in the following countries:
International Drug Name Search
Cardiosel may be available in the countries listed below.
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Cardiosel in the following countries:
International Drug Name Search
Antibioxime may be available in the countries listed below.
Cefuroxime is reported as an ingredient of Antibioxime in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
Atipamezole is reported as an ingredient of Antisedan in the following countries:
Atipamezole hydrochloride (a derivative of Atipamezole) is reported as an ingredient of Antisedan in the following countries:
International Drug Name Search
Capex is a brand name of fluocinolone topical, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Capex available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Capex.
Careflu may be available in the countries listed below.
Flunisolide is reported as an ingredient of Careflu in the following countries:
International Drug Name Search
Hydroxyzine hydrochloride (a derivative of Hydroxyzine) is reported as an ingredient of Anx in the following countries:
International Drug Name Search
Azelone may be available in the countries listed below.
Azelastine hydrochloride (a derivative of Azelastine) is reported as an ingredient of Azelone in the following countries:
International Drug Name Search
Amplisol may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Ampicillin sodium salt (a derivative of Ampicillin) is reported as an ingredient of Amplisol in the following countries:
International Drug Name Search
Magnésium Véto Veine may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Magnesium Sulfate is reported as an ingredient of Magnésium Véto Veine in the following countries:
International Drug Name Search
Provigil is a brand name of modafinil, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Provigil available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Provigil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Bumetin may be available in the countries listed below.
Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Bumetin in the following countries:
International Drug Name Search
In the US, Marcaine Spinal (bupivacaine systemic) is a member of the drug class local injectable anesthetics and is used to treat Cesarean Section and Local Anesthesia.
US matches:
Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Marcaine Spinal in the following countries:
International Drug Name Search
Alendron-Hexal may be available in the countries listed below.
Alendronic Acid is reported as an ingredient of Alendron-Hexal in the following countries:
Alendronic Acid sodium trihydrate (a derivative of Alendronic Acid) is reported as an ingredient of Alendron-Hexal in the following countries:
International Drug Name Search
Ptinolin may be available in the countries listed below.
Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ptinolin in the following countries:
International Drug Name Search
Codical may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Codical in the following countries:
International Drug Name Search
Captalin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Spiramycin is reported as an ingredient of Captalin in the following countries:
International Drug Name Search
Neuchlonic may be available in the countries listed below.
Nitrazepam is reported as an ingredient of Neuchlonic in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Deferoxamine (deferoxamine systemic) is a member of the following drug classes: antidotes, chelating agents and is used to treat Iron Poisoning - Acute and Iron Poisoning - Chronic.
US matches:
Prop.INN
V03AC01
0000070-51-9
C25-H48-N6-O8
560
Antidote: Chelating agent
Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
International Drug Name Search
Glossary
| BAN | British Approved Name |
| BANM | British Approved Name (Modified) |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
